(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release →
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boston University, Cardiometabolic Research, Chronic kidney disease, Denmark, Dr. Thomas Hanke, Evotec, Harvard University, Joslin Diabetes Center, LAB eN² Program, Mass General Brigham, metabolic syndrome, Novo Nordisk, Obesity, partnership, type 1 diabetes, Uli Stilz